Olanzapine-induced depression

Journal of Pharmacy Technology

Volumn 18, Issue 6, 2002, Pages 321-323

  Swartz, Conrad M ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; AFFECT; APATHY; ARTICLE; ASTHENIA; CASE REPORT; DEPRESSION; DRUG INDUCED DISEASE; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; MALE; MENTAL DISEASE; MOOD; RISK ASSESSMENT; SOMNOLENCE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0036862862     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250201800606     Document Type: Article

References (16)

1. Nelson LA, Swartz CM. Melancholic symptoms during concurrent olanzapine and fluoxetine. Ann Clin Psychiatry 2000;12:167-70.
2. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
3. Diagnostic and Statistical Manual of Mental Disorders. 4th Ed. Washington, DC: American Psychiatric Association, 1994.
4. Potkin SG, Buchsbaum MS, Jin Y, Tang C, Telford J, Friedman G, et al. Clozapine effects on glucose metabolic rate in striatum and frontal cortex. J Clin Psychiatry 1994;55(suppl B):63-6.
5. Cohen RM, Nordahl TE, Semple WE, Andreason P, Litman RE, Pickar D. The brain metabolic patterns of clozapine- and fluphenazine-treated patients with schizophrenia during a continuous performance task. Arch Gen Psychiatry 1997;54:481-6.
6. Li XM, Perry KW, Wong DT, Bymaster FP. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berlin) 1998;136:153-61.
7. Robertson GS, Fibiger HC. Effects of olanzepine on regional C-fos expression in rat forebrain. Neuropsychopharmacology 1996;14:105-10.
8. Centorrino F, Price BH, Tuttle M, Bahk WM, Hennen J, Albert MJ, et al. EEG abnormalities during treatment with typical and atypical antipsychotics. Am J Psychiatry 2002;159:109-15.
9. Cummings JL. Anatomic and behavioral aspects of frontal-subcortical circuits. Ann N Y Acad Sci 1995;769:1-13.
10. Paradiso S, Chemerinski E, Yazici KM, Tartaro A, Robinson RG. Frontal lobe syndrome reassessed: Comparison of patients with lateral or medial frontal brain damage. J Neurol Neurosurg Psychiatry 1999;67:664-7.
11. Swartz CM, Walder M. Hypofrontal symptoms from olanzapine: A case report. Ann Clin Psychiatry 1999;11:17-9.
12. Carpenter WT, Arango C, Buchanan RW, Kirkpatrick B. Deficit psychopathology and a paradigm shift in schizophrenia research. Biol Psychiatry 1999;46:352-60.
13. Hazlett EA, Buchsbaum MS, Jeu LA, Nenadic I, Fleischman MB, Shihabuddin L, et al. Hypofrontality in unmedicated schizophrenia patients studied with PET during performance of a serial verbal learning task. Schizophr Res 2000;43:33-46.
14. Shelton RC, Tollefson GD, Tohen M, Stahl S, Cannon KS, Jacobs TG, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-4.
15. Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen ME Long-term olanzapine therapy in the treatment of bipolar I disorder: An open-label continuation phase study. J Clin Psychiatry 2001;62:273-81.
16. Zyprexa (Olanzapine) Tablets. URL:http://www.fda.gov/cder/foi/label/2000/210861bl.pdf, p.13